Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics

@article{Cacabelos2007DonepezilIA,
  title={Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics},
  author={Ram{\'o}n Cacabelos},
  journal={Neuropsychiatric Disease and Treatment},
  year={2007},
  volume={3},
  pages={303 - 333}
}
Donepezil is the leading compound for the treatment of Alzheimer's disease (AD) in more than 50 countries. As compared with other conventional acetylcholinesterase inhibitors (AChEIs), donepezil is a highly selective and reversible piperidine derivative with AChEI activity that exhibits the best pharmacological profile in terms of cognitive improvement, responders rate (40%-58%), dropout cases (5%-13%), and side-effects (6%-13%) in AD. Although donepezil represents a non cost-effective… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 260 references

Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer’s disease and related disorders

  • E. Giacobini
  • Giacobini E, Pepeu G (eds). The Brain Cholinergic…
  • 2006
Highly Influential
20 Excerpts

Similar Papers

Loading similar papers…